Global First Release: UG2500 Optical-Mechanical & Platelet Aggregation Integrated Coagulation Analyzer

Coagulation and hemostasis are essential physiological mechanisms for maintaining blood fluidity. Their detection is significant for diagnosing coagulopathy, assessing thrombosis risk, and guiding anticoagulant and antiplatelet therapies. On March 22, 2025, at the 22nd China International In Vitro Diagnostic Expo (CACLP), Shanghai SUNBIO will unveil its latest innovation in coagulation diagnostics—the UG2500 Fully Automated Coagulation Analyzer. This cutting-edge device integrates optical, mechanical, and aggregation-based methodologies, enabling comprehensive evaluation of both primary and secondary hemostasis. The UG2500 provides a holistic solution for coagulation function assessment.

The Dual Mechanism of Hemostasis: Primary and Secondary Hemostasis

Hemostasis is a highly complex and precisely coordinated physiological process that occurs in two closely interconnected stages:

Primary hemostasis is mainly mediated by vascular contraction and the platelet system. Upon vascular injury, platelets rapidly adhere to the damaged site, become activated, and aggregate to form an initial platelet thrombus. During this process, platelets release ATP, thromboxane, and other active substances, further promoting the activation and aggregation of additional platelets.

Secondary hemostasis relies on the cascade activation of coagulation factors. Coagulation factors are activated through the intrinsic pathway (APTT) and extrinsic pathway (PT), leading to the generation of thrombin via the common pathway (TT/FIB). Thrombin converts fibrinogen into cross-linked fibrin, which firmly stabilizes the initial platelet thrombus, ultimately forming a stable blood clot and achieving hemostasis.

In clinical laboratories, hemostasis testing typically requires separate evaluation of both stages: platelet aggregation function for primary hemostasis and coagulation factor analysis for secondary hemostasis. The UG2500 Fully Automated Coagulation Analyzer enables simultaneous detection of coagulation and platelet aggregation function, perfectly meeting clinical needs for a comprehensive hemostasis assessment.

Platelet Aggregation Function Testing

Platelet aggregation plays a crucial role in primary hemostasis by forming platelet plug. Its assessment holds significant clinical value in diagnosing platelet function disorders, evaluating pre-thrombotic states, and monitoring the efficacy of antiplatelet therapy. The UG2500 employs the internationally recognized light transmission aggregometry (LTA) method to assess platelet aggregation function. By measuring the light transmission intensity changes of platelet-rich plasma under the influence of specific agonists, it quantitatively evaluates platelet aggregation capacity.

The UG2500 is equipped with five commonly used platelet aggregation agonists: arachidonic acid (AA), adenosine diphosphate (ADP), collagen (COL), epinephrine (EPI), and ristocetin (RIS). This enables a comprehensive evaluation of platelet aggregation function activated with different agonists. Such assessment is invaluable for clinicians in precisely monitoring the therapeutic effects of antiplatelet drugs (e.g., aspirin and clopidogrel), optimizing individualized treatment regimens, and enhancing perioperative treatment safety.

        Optical-Mechanical Integrated Clot Detection

  Secondary hemostasis primarily involves the cascade reactions of coagulation factors, and screening tests are typically performed using platelet-poor plasma. The UG2500 coagulation analyzer integrates both optical and mechanical method, achieving complementary advantages of the two methods:

The optical method is based on the principle of optical changes during the coagulation process. It offers advantages such as rapid detection speed, low reagent and sample consumption, and cost efficiency. This method is widely adopted by leading international brands for routine coagulation testing.

The mechanical method can minimize the impact of severe interference, such as hemolysis, icterus, and lipemia, ensuring accurate test results.

The UG2500 utilizes HIL intelligent monitoring to assess sample quality in real time. For over 90% of routine samples, it prioritizes optical detection to reduce costs. For a small subset of severely interfered samples, it automatically switches to the mechanical method, avoiding unnecessary sample dilution and retesting.

The UG2500 supports routine coagulation tests such as PT, APTT, TT, and FIB, while also enabling the measurement of coagulation factor activity, anticoagulant factors (PC, PS, and antithrombin III), lupus anticoagulant, and Anti-Xa assay, providing a comprehensive evaluation of coagulation function.

By integrating the detection functions of primary and secondary hemostasis, the UG2500 coagulation analyzer helps clinicians obtain a comprehensive picture of a patient's hemostatic and coagulation status. This provides a more reliable laboratory basis for the diagnosis and treatment monitoring of coagulation disorders, as well as for perioperative management. On March 22, 2025, at 14:10, we sincerely invite you to visit the Shanghai SUNBIO booth (8-E0301)at CACLP. Let us explore the innovative features of UG2500 firsthand and discuss the future of coagulation testing together!

About Shanghai SunBio

Founded in 2001, Shanghai Sun Biotech Co.,Ltd. specializes in the field of thrombosis and hemostasis diagnostics and is a leading global provider of comprehensive solutions in this domain. Guided by the philosophy of “Creating Products for Life,” the company is dedicated to the development, manufacturing, and sales of thrombosis and hemostasis diagnostic reagents, medical instruments, and medical consumables.

Shanghai SunBio upholds strict quality management standards and has obtained dual international certifications for ISO 9001 and ISO 13485. The company's core products hold independent intellectual property rights, with more than 100 patents in total. Additionally, SunBio actively participates in the formulation of national industry standards for PT, APTT, TT, FIB, D-Dimer, anti-Xa, and coagulation analyzers, contributing to the standardization of coagulation testing technologies. Recognized for its innovation and excellence, Shanghai SunBio has been awarded prestigious titles such as The Ministry of Industry and Information Technology (MIIT) “Little Giant” Enterprise, National High-Tech Enterprise, Shanghai Science and Technology 'Little Giant' Enterprise, and one of Shanghai’s Top 100 Smart Factories.

Looking ahead, Shanghai SunBio will continue to deepen its expertise in thrombosis and hemostasis diagnostics, driving product advancements through technological innovation, continually providing professional coagulation diagnostic solutions for global customers, and supporting the sustainable development of the healthcare industry worldwide.